<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During pregnancy, maternal floor infarction (MFI) and massive perivillous <z:mpath ids='MPATH_179'>fibrin deposition</z:mpath> (MFD) often cause fetal growth restriction and <z:hpo ids='HP_0011420'>death</z:hpo>, both being markedly increased by occlusion of the maternal intravenous circulation </plain></SENT>
<SENT sid="1" pm="."><plain>Incident rates have been reported to be in the range of 0.09-0.5% and recurrent MFI/MFD might be more frequent in early-<z:hpo ids='HP_0003674'>onset</z:hpo> cases </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, prevention measures are necessary for high-risk women who have had MFI/MFD as complications in a previous pregnancy </plain></SENT>
<SENT sid="3" pm="."><plain>In this report, the use of oral low-dose aspirin at the early trimester and low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> drip infusion from the mid-second trimester was examined for this purpose </plain></SENT>
</text></document>